METFORMIN,VILDAGLIPTIN

Metformin and vildagliptin are used in the management of type 2 diabetes mellitus and hyperglycemia. The combination helps improve blood glucose control and insulin sensitivity and may support weight management.

Metformin + Vildagliptin is primarily used to manage type 2 diabetes mellitus. Specifically, it controls hyperglycemia and improves insulin sensitivity in patients with this condition.

Metformin + Vildagliptin is administered orally as tablets and is available in the strength of 50mg/500mg. The recommended starting dosage and any necessary dose adjustments are determined based on the specific condition being treated and the patient's response to the medication.

Metformin + Vildagliptin may cause several side effects, varying in severity. Common side effects include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal discomfort. Additionally, individuals may experience headaches, dizziness, weakness, and a metallic taste in the mouth. More serious but rare side effects may include lactic acidosis, which can be life-threatening, and severe allergic reactions characterized by rash, itching, swelling, dizziness, and breathing difficulties.

Lactic acidosis, a rare but potentially serious condition, is risky after using Metformin + Vildagliptin. The risk of hypoglycemia increases when it is combined with other antidiabetic medications.

Seek immediate medical attention if symptoms such as muscle pain, weakness, abdominal discomfort, hyperventilation, or unusual sleepiness occur after taking Metformin + Vildagliptin. Close monitoring of blood sugar levels is crucial, especially during the initial phase of treatment.

Kidney function should be monitored regularly, as metformin and vildagliptin are eliminated through the kidneys. Hypoglycaemia risk is increased, particularly when combined with other diabetes medications, and requires careful observation. Symptoms of lactic acidosis warrant immediate medical attention. Metformin should be temporarily discontinued prior to administration of contrast agents during medical imaging. Use with caution in patients with hepatic impairment and monitor for signs of infection. Healthcare providers must be informed of this medication before undergoing surgery or medical procedures. Allergic reactions are possible and should be reported promptly. Vitamin B12 deficiency may develop during prolonged use; monitoring and supplementation should be considered as clinically indicated. Adequate hydration is important, especially during acute illness or exposure to high temperatures, to reduce the risk of dehydration-related complications. Medical management may require adjustment during periods of physiological stress, including surgery or infection. Exercise caution in pregnancy and lactation; the risks and benefits should be discussed with a healthcare provider.

Pharmadox Healthcare Ltd., Electronic Medicines Compendium (EMC), [Revised on August 2023] [Accessed on 22nd Oct 2023], https://www.medicines.org.uk/emc/files/pil.14380.pdf Galenicum Health, S.L, [Revised on April 2023] [Accessed on 22nd Oct 2023], https://medicinesauthority.gov.mt/file.ashx?f=0594EAF2C2622B403776FD1C302BFCBAFBF6CB6184EDD15C Martha S. Nolte Kennedy, Umesh Masharani, Pancreatic Hormones & Anti-diabetic Drugs, Lange’s Basic & Clinical Pharmacology, 14th Edition, 2018, 747-771. KD Tripathi, Insulin, Oral Antidiabetic Drugs and Glucagon, Essentials of Medical Pharmacology, 8th Edition, 2019, 280-305.